A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Day One Biopharmaceuticals, Inc.
DAWN
$975M
Mkt Cap
Day One Biopharmaceuticals, Inc. (DAWN) has a market capitalization of $1.0B. It is classified as a small-cap stock.
Day One Biopharmaceuticals, Inc. (DAWN) does not currently pay a regular dividend.
Day One Biopharmaceuticals, Inc. (DAWN) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Day One Biopharmaceuticals, Inc. (DAWN) has a net profit margin of -67.8%. The company is currently unprofitable.
Day One Biopharmaceuticals, Inc. (DAWN) generated $-104 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Day One Biopharmaceuticals, Inc. (DAWN) has a debt-to-equity ratio of 0.01. This indicates a conservatively financed balance sheet.
Day One Biopharmaceuticals, Inc. (DAWN) reported earnings per share (EPS) of $-1042.14 in its most recent fiscal year.
Day One Biopharmaceuticals, Inc., or the Company or Day One, is a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases. At Day One, we aim to identify and develop breakthrough medicines with the goal of improving the outcomes and life trajectories of patients of any age facing serious diseases — starting from Day One. Our “search & development” strategy enables us to find, acquire, and develop potential best- or first-in-class programs with the goal of introducing new medicines that will make a real difference in the treatment of children and adults. Our first commercial product, tovorafenib, is an oral, brain-penetrant, highly selective type II rapidly accelerated fibrosarcoma, or RAF, kinase inhibitor. Tovorafenib was granted breakthrough therapy designation by the U.S.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | 0 | 0 | - |
| Net Income | -107.3B | -107.3B | -95.5B | -188.9B | -142.2B | -72.8B |
| EPS | $-1,042.14 | $-1,042.14 | $-944.42 | $-2,165.81 | $-1,935.54 | $-1,174.36 |
| Free Cash Flow | -104M | -104M | -80M | -147M | -110M | -49M |
| ROIC | 0.0% | - | - | - | - | - |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.00 | - | - |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 0 | - | - | - | - | - |
| Operating Margin | 0.0% | -80.8% | -165.7% | - | - | - |
| ROE | -24327.1% | -24327.1% | -18994.7% | -54515.2% | - | - |
| Shares Outstanding | 103M | 103M | 101M | 87M | 73M | 62M |
| Metric | ||||||||
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | N/A | N/A | N/A | 0 | 0 | N/A | N/A | 0 |
| Gross Margin | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 14M | 9.1M | 44M | 86M | 131M | 228M | 148M | 148M |
| SG&A | 1.0M | 4.7M | 29M | 61M | 76M | 115M | 121M | 121M |
| EBIT | -15M | -14M | N/A | N/A | N/A | N/A | N/A | 0 |
| Op. Margin | 0.0% | N/A | N/A | N/A | N/A | -165.7% | -80.8% | 0.0% |
| Net Income | -13M | -41M | -72.8B | -142.2B | -188.9B | -95.5B | -107.3B | -107.3B |
| Net Margin | 0.0% | N/A | N/A | N/A | N/A | -72.8% | -67.8% | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | -71K | -71K |
| Returns on Capital | ||||||||
| ROIC | N/A | -30.2% | N/A | N/A | N/A | N/A | N/A | 0.0% |
| ROE | 233.5% | 124.9% | N/A | N/A | -54515.2% | -18994.7% | -24327.1% | -24327.1% |
| ROA | N/A | -88.7% | -43372.8% | -44509.2% | -52107.1% | -19919.2% | -19681.0% | -21133.6% |
| Cash Flow | ||||||||
| Op. Cash Flow | -4.5M | -13M | -49M | -110M | -147M | -78M | -104M | -104M |
| Free Cash Flow | -4.5M | -14M | -49M | -110M | -147M | -80M | -104M | -104M |
| Owner Earnings | -4.6M | -14M | -62M | -137M | -186M | -127M | -149M | -149M |
| CapEx | 0 | 92K | 0 | 26K | 224K | 2.2M | 320K | 320K |
| Maint. CapEx | 0 | 16K | 20K | 63K | 36K | 92K | 366K | 366K |
| Growth CapEx | N/A | 76K | N/A | 0 | 188K | 2.1M | 0 | 0 |
| D&A | 0 | 16K | 20K | 63K | 36K | 92K | 366K | 366K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 111K | 526K | 13M | 27M | 39M | 48M | 45M | 45M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||
| Net Debt | N/A | -43M | -284M | -341M | -366M | -529M | -438M | -194M |
| Cash & Equiv. | 27M | 44M | 284M | 85M | 231M | 125M | 197M | 197M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 2.8M |
| Debt/Equity | -1.00 | -0.01 | N/A | N/A | 0.00 | 0.01 | 0.01 | 0.01 |
| Interest Coverage | -7.2 | -459.4 | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | -11M | -54M | N/A | N/A | 347M | 503M | 441M | 441M |
| Total Assets | 0 | 46M | 290M | 349M | 376M | 583M | 508M | 508M |
| Total Liabilities | 11M | 100M | N/A | N/A | 30M | 80M | 67M | 67M |
| Intangibles | N/A | N/A | N/A | N/A | 0 | 16M | 18M | 18M |
| Retained Earnings | N/A | -57M | -127M | -270M | -459M | -554M | -661M | -661M |
| Working Capital | N/A | 43M | 281M | 331M | 346M | 489M | 425M | 425M |
| Current Assets | N/A | 45M | 289M | 348M | 375M | 562M | 485M | 485M |
| Current Liabilities | N/A | 2.0M | 8.7M | 17M | 30M | 73M | 61M | 61M |
| Per Share Data | ||||||||
| EPS | -2.13 | -7.33 | -1,174.36 | -1,935.54 | -2,165.81 | -944.42 | -1,042.14 | -1,042.14 |
| Owner EPS | -0.78 | -2.54 | -1.00 | -1.87 | -2.14 | -1.25 | -1.44 | -1.44 |
| Book Value | -1.80 | -9.81 | N/A | N/A | 3.97 | 4.97 | 4.28 | 4.28 |
| Cash Flow/Share | -0.76 | -2.44 | -0.78 | -1.50 | -1.68 | -0.77 | -1.01 | -1,042.13 |
| Dividends/Share | 0.00 | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 5.9M | 5.5M | 62.0M | 73.5M | 87.2M | 101.1M | 103.0M | 103.0M |
| Valuation | ||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -0.0 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | N/A | 3.4 | 2.4 | 2.2 | 2.3 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | 10.3 | 5.4 | N/A |
| FCF Yield | N/A | N/A | -8.1% | -8.5% | -12.3% | -6.7% | -10.7% | -10.1% |
| Market Cap | 0 | N/A | 601M | 1.3B | 1.2B | 1.2B | 975M | 1.0B |
| Avg. Price | 0.00 | N/A | 22.13 | 16.35 | 14.50 | 14.45 | 8.21 | 10.03 |
| Year-End Price | 0.00 | N/A | 16.27 | 19.81 | 14.99 | 12.87 | 9.45 | 10.03 |
Day One Biopharmaceuticals, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Day One Biopharmaceuticals, Inc. (DAWN) has a return on equity (ROE) of -24327.1%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 7 years of financial data for Day One Biopharmaceuticals, Inc. (DAWN), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Day One Biopharmaceuticals, Inc. (DAWN) has a book value per share of $4.28, based on its most recent annual SEC filing.